Lecanemab and Donanemab as Therapies for Alzheimer’s Disease: An Illustrated Perspective on the Data

Alberto J. Espay, Kasper P. Kepp, Karl Herrup*

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

11 Downloads (Pure)

Abstract

Treatment of Alzheimer’s disease by targeting the antiamyloid beta (Aβ) peptide with immunotherapy has led to Food and Drug Administration approval of several new Aβ monoclonal antibodies. These approvals have come with restrictions, but the uptake of these new therapies in the clinic is expected to increase rapidly, at least in the USA. Hailed as a “breakthrough” by some, there has been stiff coun-tercommentary questioning both safety and efficacy. The authors of this piece have been among those most concerned about the wisdom of releasing these drugs for clinical use. We note that the debate has been thus far largely confined to the clinical literature. With this Social Issues commentary, the authors hope to bring the basic science research community into the discussion.

Original languageEnglish
Article numberENEURO.0319-23.2024
JournaleNeuro
Volume11
Issue number7
Number of pages6
ISSN2373-2822
DOIs
Publication statusPublished - 2024

Keywords

  • Aducanumab
  • Alzheimer’s disease
  • Antiamyloid monoclonal antibodies
  • Beta-amyloid
  • Donanemab
  • Lecanemab

Fingerprint

Dive into the research topics of 'Lecanemab and Donanemab as Therapies for Alzheimer’s Disease: An Illustrated Perspective on the Data'. Together they form a unique fingerprint.

Cite this